RSV Prevention Update: ACIP/AAP Recommendations for Nirsevimab in Infants and RSV Vaccine in Pregnancy

• 2023

  Log in to bookmark this resource.

  Log in
• Joseph Bocchini

---

Access Resources

• LectureEN
• Ask aRCie About This Resource

About

These presentation slides provide information for physicians about recommendations for nirsevimab for prevention of serious lower respiratory tract infection from respiratory syncytial virus (RSV) in infants. It discusses drug details, clinical trial results, adverse events, dosage formulations, guidance for pregnant women, and information about the Vaccines for Children (VFC) program.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant; Infant, Newborn; Pregnant Women; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Vaccination; Immunization Programs; Respiratory Syncytial Virus, Human; Palivizumab; Antibodies, Monoclonal, Humanized

Institutions: Tulane University; Louisiana Department of Health

---

More like this

Wastewater Monitoring for Infectious Disease: Intentional Relationships Between Academia, the Private Sector, and Local Health Departments for Public Health Preparedness 2023 · Wayne State University Chemical-Biological Terrorism and Its Impact on Children [2020] 2020 · Harvard Medical School, Boston Children's Hospital, Yale University, Children's Hospital Colorado, University of Colorado, American Academy of Pediatrics (AAP) Nirsevimab Updates 2024 · Hawaii State Department of Health

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---